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Tuberculosis (TB) remains a major challenge to
global public health and has proved particularly
difficult to control in regions with high HIV preva-
lence. Of the estimated global burden of 9.3 million
new TB cases in 2007, 1.37 million (14.8%) were
associated with HIV.1,2 TB remains a major cause
of mortality, with an estimated 1.3 million deaths
among individuals who are not infected with HIV
and a further 0.5 million TB deaths among people
who have HIV. The latter accounted for almost
25% of global AIDS-related mortality.
HIV was a key factor underlying the approxi-
mately 1% annual increase in global TB incidence
rates between 1990 and 2004. Sub-Saharan
Africa has borne the brunt of this co-epidemic,
accounting for 79% of cases of the global burden
of HIV-associated TB in 2007. Here TB notification
rates have increased three- to fivefold in many
countries, especially in the south of the continent
where HIV prevalence is highest. As a result, TBS. D. Lawn and K. Kranzer are funded by the Wellcome
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observed in most other parts of the world (Fig. 1).
Elsewhere, South and East Asia account for 11%
of the global burden of HIV-associated TB and
the combined epidemics of HIV and drug resistant
TB are undermining TB control in Eastern Europe.1
MILLENNIUM DEVELOPMENT GOALSFOR TUBERCULOSIS CONTROL
The Millennium Development Goals (MDG) TB
control targets are to halt and start to reverse the
rising incidence of TB and to halve the 1990 prev-
alence and death rates by 2015.3 Although the
absolute number of TB cases occurring worldwide
continued to increase in 2007, it was largely the
result of global population growth. Global TB inci-
dence rates are actually thought to have peaked in
2004 at 142 cases per 100,000 population and to
have started to slowly decrease thereafter.1,2
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Fig. 1. Estimated TB incidence rates by country for 2006. (Reproduced from World Health Organization. Global
Tuberculosis Control. Surveillance, planning, and financing. WHO/HTM/TB/2008.393. Geneva (Switzerland): World
Health Organization; 2008; with permission.)
Lawn et al686global TB prevalence since 1990.1 Rates of TB
mortality (HIV-associated and non-HIV–associ-
ated) are also estimated to have peaked around
the year 2000 and have since decreased.1
Despite these encouraging overall trends,
however, the global MDG TB control target of
halving the 1990 TB prevalence and death rates
by 2015 will not be achieved with current rates
of progress.3 Targets are projected to be missed
in the regions of sub-Saharan Africa and Eastern
Europe where the TB and HIV epidemics inter-
sect. Concerted international public health action
is needed.INTERNATIONAL PUBLIC HEALTH RESPONSE
Since the World Health Organization (WHO)
declaration in 1993 that TB was a global emer-
gency, the directly observed treatment, short-
course (DOTS) strategy has served as the key
public health intervention that has been widely im-
plemented to effect global TB control.4 This
strategy prioritizes the detection of patients who
are sputum smear-positive presenting to health
facilities with symptoms and aims to achieve
high cure rates using short-course rifampicin-con-
taining chemotherapy. Although this has been
effective in most parts of the world, contributing
to the sustained downward trend in global
TB prevalence, it has nevertheless beencomparatively ineffective in countries with high
HIV prevalence.1,2,5,6 Although the DOTS strategy
remains the foundation for TB control programs in
high HIV-prevalence settings, it is clear that addi-
tional interventions are needed.
Under the leadership of the WHO and the Stop-
TB Partnership, TB-HIV guidelines,7 a TB-HIV stra-
tegic framework,8 and an interim TB-HIV policy9
were published between 2002 to 2004 to address
the challenge of HIV-associated TB in severely
affected countries. The aim of these interventions
is to reduce the burden of TB in people who
are HIV-infected through use of TB prevention
strategies, such as isoniazid preventive therapy,
intensified case finding, infection control, and anti-
retroviral therapy (ART). A further aim is to reduce
the impact of HIV in patients who have TB through
HIV testing and use of trimethoprim-sulfamethox-
azole prophylaxis and ART.
Great progress has been made over the past
few years in HIV testing in patients who have TB1
and in the scale-up of ART.10 More than 3 million
people in resource-limited settings were estimated
to have started ART by the end of 2007 and
2 million of these were in sub-Saharan Africa.10
However, little is known about what impact this
massive public health intervention will have on
the HIV-associated TB epidemic or how ARTmight
be used to best effect TB control. This article
provides an in-depth review of these issues.
Antiretrovirals for HIV-Tuberculosis Control 687TUBERCULOSIS INCIDENCE RATES INANTIRETROVIRALTREATMENT COHORTS
Data from 12 observational studies that included
over 32,000 participants living in high-income
countries (seven studies) and resource-limited
countries (five studies) are shown in Table 1. In
two of these studies, TB rates were simply
compared before and after 1995 when triple-
drug ART was introduced, whereas in the remain-
ing studies TB rates were determined according to
person-time of exposure to ART. All but two of
these studies found a statistically significant
reduction in TB risk during ART.
In nine studies, the reductions in TB risk associ-
ated with use of antiretrovirals are expressed as
hazard ratios adjusted for covariates, such as base-
line patient characteristics and antiretroviral
regimen. Triple-drug ART was associated with
a risk reduction of more than 70% in the majority
of these studies (n 5 6) with a range of 54% to
92% (see Table 1). This protective effect against
TB was seen in countries with low-TB burden,
such as the United States,11 and South Africa,12
which has the highest burden of HIV-associated
TB in the world.2 The benefits of ART are seen
across a broad range of degrees of baseline immu-
nodeficiency and clinical stage of disease, although
the absolute reduction in TB rates is greatest in
those with the most advanced HIV disease (Fig. 2).
TB incidence rates in 14 ART cohorts are shown
in Table 2. The observed rates are heterogeneous
and are likely to vary according to the local TB inci-
dence rates, the baseline degree of immunodefi-
ciency, and the duration of ART. Several studies
report rates stratified according to duration of ART
and these are shown in Fig. 3. The figure illustrates
the major differences between TB rates in various
settings and the rapidity of the beneficial impact of
ART. All of these studies show time-dependent
reductions in TB rates, with most of the benefit
occurring within the first 2 years of ART.13–19
Although reductions in TB incidence in high- and
low-TB burden settings are proportionately
similar,15 the greatest absolute reductions in TB
risk of course occur in high-TB prevalence settings.
Baseline risk factors for incident TB during ART
in resource-limited settings included low-CD4 cell
count,12–15 advanced WHO stage of disease,12,14
younger age,14,15 low socioeconomic status,12
past history of TB,20 and male sex.15 In high-
income countries, baseline risk factors for TB
included low-baseline CD4 count and HIV trans-
mission category.15,18 However, the risk of TB
decreased as CD4 cell counts rose (Fig. 4). Thus,
with increasing duration of treatment, the immuno-
logic response to ART, rather than baselinepatients’ characteristics, emerges as the dominant
predictor of TB risk.13 The strong relationship
between TB rates and updated CD4 cell counts
during ART is shown in Fig. 5.19
Data are scarce concerning TB rates among
those with optimum immune recovery. However,
in a study in South Africa, subjects achieving
CD4 cell counts of greater than 500 cells/mL
retained a TB rate that was approximately two-
fold higher than that in subjects who were non-
HIV–infected living in the same community.19
These data suggest that recovery of TB-specific
immune function during ART may be incomplete
even at high CD4 cell counts.
ANTIRETROVIRALS AND TUBERCULOSISINCIDENCE ATA COMMUNITY LEVEL
Despite the extensive data that have arisen from
observational cohort studies, empiric data
regarding the impact of ART on TB incidence rates
at the community level are lacking. This is a difficult
issue to study. In-depth observational studies of
sentinel communities with high TB and HIV preva-
lence during scale-up of ART are needed.
Outcome measures should include the impact of
ART scale-up on TB incidence and prevalence,
TB transmission, and TB-associated mortality.
However, trends in TB incidence and mortality
over time will inevitably be confounded by other
variables, such as the natural evolution of the HIV
epidemic, changes over time in socio-economic
factors, and the efficiency of TB control programs.
Ecological studies comparing settings differing in
the rapidity and coverage of ART scale-up may
provide further insights.
LIKELY LIMITED IMPACT OFANTIRETROVIRALSAT COMMUNITY LEVEL
Despite the major beneficial impact of ART on
TB rates in observational cohorts, mathemat-
ical modeling studies suggest that the impact
of ART on TB rates at a population level will be
limited.21 Various observations suggest that
this conclusion is likely to be true22 and are
discussed in full in Box 1.Risk of Tuberculosis Before Starting
Antiretroviral Treatment
Following HIV seroconversion, risk of TB doubles
and continues to increase as CD4 cell counts
decline.12,23–25 Patients, therefore, typically
remain at a high risk of TB for many years before
eligibility for ART. Further compounding this, HIV
infection is often only diagnosed once patients
T ble1S dies (n5 12) reporting the impact of antiretroviral therapy on tuberculosis incidence rates in observational cohorts
S dy Setting N Study Period Study Design Impact of ARTonTBIncidence Rates Adjusted HazardsRatio (95%CI)
S dies comparing TB rates in cohorts before and after introduction of ART
B odt et al, 199757 Germany 1003 1992–1996 Cohort of homosexual men
1992–1996
No change in overall cohort
incidence rates (range,
2.1–2.7 cases/100 PY)
–
K rk et al, 200058 Europe 6,972 1994–1999 EuroSIDA multicenter
cohort 1994–1999
Overall rate in cohort
decreased from 1.8
cases/100 PY to 0.3
cases/100 PY
–
S dies comparing TB rates in patients receiving or not receiving ART
L dergerber et al, 199917 Switzerland 2410 1995–1997 Swiss HIV Cohort Study Rate 0.78 cases/100 PY pre-
ART and 0.22 cases/100
PY during first 15 months
ART
–
J nes et al, 200011 United States – 1992–1998 Multicenter cohort Adult/
Adolescent Spectrum of
HIV Disease project
Steep decreases in TB
incidence rates
0.2 (0.1–0.5)
G rardi et al, 200059 Italy 1360 1995–1996 Multicenter cohort Not stated 0.08 (0.01–0.88)
S ntoro-Lopes et al, 200260 Brazil 255 1991–1998 Prospective cohort Not stated 0.2 (0.04–1.13)
B dri et al, 200212 South Africa 1034 1992–2001 Rates compared in
separate prospective
observational cohorts
receiving or not receiving
ART
Markedly lower TB rates
across a broad spectrum
of baseline CD4 counts
and WHO stage
0.19 (0.09–0.38)
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Golub et al, 200740 Brazil 11,026 2003–2005 Multicenter retrospective
cohort
Rates among those
receiving and not
receiving ART were 1.9
and 4.0 cases/100 PY,
respectively
0.46 (0.33–0.63)
Miranda et al, 200761 Brazil 463 1995–2001 Multicenter retrospective
study
Rates among those
receiving and not
receiving ART were 1.2
and 13.4 cases/100 PY,
respectively
0.2 (0.1–0.6)
Muga et al, 200762 Spain 2238 1980s–2004 Multicenter seroconverter
cohort
Marked reduction in rates
after 1995 in all HIV
transmission categories
0.31 (0.17–0.54)
Moreno et al, 200863 Spain 4268 1997–2003 Multicenter hospital-based
cohort
Rates among those
receiving and not
receiving ART were 0.5
and 1.6 cases/100 PY,
respectively
0.26 (0.16–0.40)
Golub et al, 200964 South Africa 2778 2003–2007 Retrospective data from
two study sites
Rates among those
receiving and not
receiving ART were 4.6
and 7.1 cases/100 PY,
respectively
0.36 (0.25–0.51)
Abbreviation: PY, person-years.
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Fig. 2. TB incidence (cases per 100 person-years)
among patients who were HIV-infected in Cape
Town, South Africa, who were or were not receiving
antiretroviral therapy. Patients were stratified accord-
ing to baseline CD4 cell count and WHO stage of
disease. Overall, TB rates were approximately 80%
lower among those receiving ART, which was
observed across a broad spectrum of baseline immu-
nodeficiency. (Data from Badri M, Wilson D, Wood
R. Effect of highly active antiretroviral therapy on
incidence of tuberculosis in South Africa: a cohort
study. Lancet 2002;359(9323):2059–64).
Lawn et al690present to medical services with advanced immu-
nodeficiency and either have active TB or high risk
of developing TB in the short term.26
In addition to TB occurring before enrollment for
ART, a substantial burden of prevalent TB may be
diagnosed in ART services during screening
before starting treatment.13,16,27,28 The proportion
detected may vary according to the intensity of
investigation and availability of mycobacterial
culture. In two studies from South Africa, 20% to
25% of adults referred for ART who did not already
have a TB diagnosis were found to have sputum
culture-positive TB, the majority of which was
smear-negative.27,28
The overall cumulative risk of TB before initiating
ART may therefore be very high. In one ART
service in Cape Town, this represented two thirds
of adult patients.13 Thus, ART is frequently imple-
mented too late in the course of HIV progression
to prevent much of the overall burden of HIV-
associated TB.
Incidence of Tuberculosis During
Antiretroviral Therapy
In addition to TB occurring pre-ART, TB incidence
rates during ART persist at rates substantially
higher than background (see Table 2). During the
initial months of treatment, a proportion of TB
cases present as a result of the unmasking of
subclinical TB during ART-induced restoration of
TB-specific immune responses.19,29,30 Throughthis mechanism, the risk of TB during ART may
actually increase in the short term after starting
ART. However, the size of this effect will be highly
dependent on the efficiency with which patients
are screened for clinical and subclinical TB before
commencing ART. Unmasking TB was estimated
to account for more than one third of the TB cases
presenting during the first 4 months of ART in
a treatment service in South Africa.19
In the longer term, TB rates during ART appear
to be largely dependent on changes in the CD4
cell count over time. With CD4 cell counts less
than 200 cells/mL, TB rates exceeded 9.0 cases/
100 person-years (PY) in the same study from
South Africa.19 Rates at higher CD4 counts were
substantially lower, but nevertheless remained
more than five-fold higher than rates in individuals
who were non-HIV-infected living in the same
community.13,19
Persistence of high TB rates in ART cohorts is
likely to reflect the fact that most patients spend
prolonged periods at CD4 cell counts less than
500 cells/mL. In addition, immunologic studies
also suggest that defects in functional TB-specific
immune responses may persist despite ART,31
leaving patients vulnerable to TB long-term. This
may be compounded by high rates of nosocomial
exposure to TB within overcrowded ART services
where infection control procedures are often
lacking.32,33
Despite high early mortality risk,34 long-term
survival after the first year of ART is likely to be
good in patients who are in treatment programs
in sub-Saharan Africa. In light of the persistence
of high rates of TB during ART, the life-time cumu-
lative risk of TB in survivors will inevitably be high.
It is not yet clear whether this is reduced
compared with the cumulative life-time risk in
patients who are HIV-infected in the pre-ART era.
A further critical factor affecting the magnitude
of the impact of ART on community TB rates is
the coverage of ART. In mathematical modeling
studies, high coverage with ART was needed to
impact TB rates.21 However, coverage in sub-Sa-
haran Africa was only approximately one third of
those estimated to be in need at the end of
2007.10 In most countries, rates of HIV-testing
are low and only a small proportion of individuals
who are HIV-infected know their HIV status.
Themagnitude of any impact of ARTon TB trans-
mission is unknown. It has been generally assumed
that patients who are HIV-infected are not the key
drivers of TB transmission in the community in
view of their comparatively low infectivity. If true
then ART is unlikely to have a major impact on
community TB transmission. Conversely, however,
patients receiving ART survive longer and remain at
Table 2Studies (n514) reporting tuberculosis incidence rates during antiretroviral therapy
Study Setting N
Median / MeanFollow-up (Months) Median Baseline CD4Cell Count (Cells/mL)
TB Cncidence, Cases/100 PY (Monthsof ART)
Estimated NationalTB Incidence Rate (Per100 Population)a
High-income countries
Girardi et al, 200518 Germany,
Switzerland,
France,
Netherland, UK,
Canada, United
States
17,142 25.8 280 1.31 (0–3)
0.78 (4–6)
0.46 (7–12)
0.33 (13–24)
0.15 (25–36)
0.005–0.016
Brinkhof et al, 200715 Europe, North
America
22,217 11.0 234 1.7 (0–3)
1.0 (4–6)
0.6 (7–12)
<0.015
Moreno et al, 200863 Spain 4268 46.0 324 0.5 0.035
Resource-limited settings
Badri et al, 200212 South Africa 1034 16.8 254 2.4 0.406
Santoro-Lopes et al,
200260
Brazil 284 22.0 – 8.4 0.071
Lawn et al. 200514 South Africa 346 40.0 242 3.35 (0–12)
1.56 (13–24)
1.36 (25–36)
0.90 (37–48)
1.01 (49–60)
0.576
Seyler et al, 200520 Coˆte d’Ivoire 129 26.0 125 4.8 0.368
Lawn et al, 200613 South Africa 1002 0.9 96 23.0 (0–3)
10.7 (4–6)
7.0 (7–12)
3.7 (13–24)
0.898
(continued on next page)
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Table 2
(continued)
Study Setting N Median / Mean Follow-up (Months) Median Baseline C 4Cell Count (Cells/m )
TB Cncidence, Cases/100 PY (Monthsof ART)
Estimated NationalTB Incidence Rate (Per100 Population)a
Bonnet et al, 200665 Kenya
Malawi
Cameroon
Thailand
Cambodia
3151 3.7
6.7
11.1
3.7
7.3
– 17.6
14.3
4.8
10.4
7.6
0.419
0.416
0.194
0.142
–
Golub et al, 200740,64 Brazil 11,026 17.0 – 1.90 0.053
Miranda et al, 200761 Brazil 245 – – 1.2 0.064
Brinkhof et al, 200715 Botswana, Brazil,
Coˆte d’Ivoire,
India, Kenya,
Nigeria, Malawi,
Morocco, Senegal,
South Africa,
Thailand, Uganda
4540 9.6 107 10.7 (0–3)
7.5 (4–6)
5.2 (7–12)
0.055–0.852
Moore et al, 200716 Uganda 1044 17.0 127 3.9 (overall)
7.5 (0–6)
2.4 (7–12)
1.9 (13–18)
0.385
Walters et al, 200866 South Africa 290 (pediatric) – – 6.4 0.898
Abbreviation: PY, person-years.
a National TB incidence estimates at the midpoint of the study duration; data sourced from World Health Organizati . Global tuberculosis control: epidemiology, strategy,
financing. Geneva (Switzerland): World Health Organization; 2009. WHO/HTM/TB/2009.411.
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Fig. 3. TB incidence rates during ART. The graph shows
data from studies included in (see Table 2) in which
changing TB incidence rates were calculated accord-
ing to increasing duration of ART. The two lowest
curves present data from studies conducted in high-
income countries.15,18 The remaining four studies are
from South Africa (diamonds13 and inverted trian-
gles14), a range of resource-limited countries
(circles15), and Uganda (squares16).
Antiretrovirals for HIV-Tuberculosis Control 693substantial risk of TB that may be more likely to be
sputum smear-positive as immune function
improves. However, transmission risk among
such patients remains undefined.
Perhaps the most important issue relating to TB
transmission is that occurring between individuals
who are HIV-infected in health care settings.33 This
issue was exemplified by the outbreak of multi-
drug-resistant and extensively drug-resistant TB
in a hospital-based ART service in rural South Afri-
ca from 2005 to 2006.32 Although ART may serve
as a potent preventive therapy for TB, ART0
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Fig. 4. Decreasing TB incidence rates (cases/100 person-ye
(cells/mL, black diamonds) during the first 3 years of ART.
in a township in Cape Town, South Africa. (Data from Reservices without adequate infection-control
measures may nevertheless be sites associated
with high risk of nosocomial TB transmission and
outbreaks.ENHANCING THE IMPACT OFANTIRETROVIRALSON TUBERCULOSIS CONTROL
Earlier Initiation of Antiretroviral Therapy
It is likely that ART could be used much more
effectively as a TB-prevention strategy (Box 2).
ART should be initiated much earlier in the course
of disease than is currently being done. In sub-
Saharan Africa, the median CD4 cell count at
baseline in ART programs is often in the range of
100 to 150 cells/mL34 and many patients have
already had TB before starting ART. Earlier HIV
diagnosis would permit more timely initiation of
ART, thereby enhancing its role as a preventive
intervention. Consideration should be given to
revision of ART eligibility guidelines in countries,
such as South Africa, where treatment is restricted
to patients who have WHO stage 4 disease or
blood CD4 cell counts of less than 200
cells/mL.35 A randomized controlled trial of early
(CD4 200–350 cells/mL) versus late (CD4 <200
cells/mL) initiation of ART in Haiti was discontinued
in 2009 following interim analysis.36 In the delayed
initiation group, the mortality was fourfold higher
and the TB incidence rate was twofold higher
than in the early initiation group, clearly demon-
strating the benefits to be derived from earlier
treatment.
A mathematical modeling study explored the
potential impact of a test and treat strategy2 3
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Fig. 5. Relationship between updated CD4 cell-count measurements made every 4 months during 4.5 years of ART
in a treatment cohort in a township in Cape Town, South Africa. Observed rates are shown as diamonds together
with 95% confidence intervals indicated by bars. A logarithmic trend line is overlaid (R2 5 0.97). TB incidence
rates are seen to fall substantially as CD4 cell counts increase during ART. (Data from Lawn SD, Myer L,
Edwards D, et al. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antire-
troviral therapy in South Africa. AIDS 2009;23(13):1717–25.)
Lawn et al694whereby all patients who are diagnosed with HIV
are immediately offered ART irrespective of the
blood CD4 cell count.38 Although interest has
primarily focused on the potential of such
a strategy for HIV prevention, this also has the
potential to impact TB control. The rapidity of
scale-up of ART may also be an important variable
that affects not only the numbers of deaths averted
by ART39 but also the number of TB cases averted.Adjunctive Interventions
Because TB rates do not decrease to background
levels during long-term ART, use of concurrent
adjunctive interventions is needed. Three key
interventions are encompassed within the WHO
3I’s strategy launched in April 2008.37 This three-Box1Reasonswhy scale-up of antiretroviral therapy islikely to have only limited impact on tuberculosisincidence rates at the community level
 Much HIV-associated TB occurs before initia-
tion of ART
 High rates of TB persist during ART
 Prolonged survival of patients on ART is asso-
ciated with a high life-time cumulative risk of
TB
 Limited coverage of ART in the community
and limited compliance with treatment
 Impact of ART on TB transmission in the
community is suspected to be lowpronged strategy includes intensified case finding,
isoniazid preventive therapy, and infection control.
Intensified case finding is needed in ART
services as this designates patients as either
having active TB (and in need of treatment) or
being TB-free and potentially benefitting from
isoniazid preventive therapy. Initiation of TB treat-
ment in thosewho have disease also plays a critical
role in reducing the risk of nosocomial TB trans-
mission. Observational data have examined the
potential role of isoniazid preventive therapy
concurrently with ART in Brazil. Although isoniazid
alone was not associated with significant reduc-
tions in TB risk compared with the nonintervention
group, it was suggested that concurrent isoniazid
preventive therapy during ART provided an addi-
tive benefit.40 However, this requires confirmation
by randomized controlled trials.Box 2Potential ways to enhance the impact ofantiretroviral therapy on tuberculosis preventionat a community level
 Diagnose HIV earlier and initiate ART at
higher CD4 cell counts
 Increase coverage of ART in the community
 Increase rapidity of scale-up of ART
 Use of adjunctive interventions with ART,
such as those included within the WHO 3I’s
strategy (intensified case finding, isoniazid
preventive therapy and infection control)37
Table 3Observational cohort studies (n58) showing the impact of antiretroviral therapy onmortality among patients who have HIV-associated tuberculosis
Study Country Study Design Outcome
Dheda et al, 200467 United Kingdom Retrospective study of patients who had HIV-TB
(n 5 99) treated in pre-ART era and in ART era
Adjusted hazards of death or new AIDS-defining illness
was 0.34 (95%CI, 0.18–0.63) during ART era
Manosuthi et al, 200668 Thailand Retrospective cohort study (n 5 1003) comparing
mortality in a historic natural- history cohort with
rates in an ART cohort
The adjusted hazards of death associated with use
of ART was 0.05 (95%CI, 0.02–0.12).
Akksilp et al, 200769 Thailand Prospective cohort (n 5 329) comparing patients
receiving and not receiving ART
Adjusted hazards of death was 0.2 (95%CI, 0.1–0.4)
Zachariah et al, 200743 Malawi Retrospective observational cohort in which
a proportion of patients started ART during the
continuation phase of TB treatment (n 5 658)
No difference in mortality between patients who chose
or did not choose to receive ART, but potential
allocation bias according to degree of
immunodeficiency and most deaths occurred pre-
ART during intensive phase
Nahid et al, 200749 United States Retrospective observational cohort (n 5 264) 1990–
2001 spanning pre-ART and ART era
Use of ART protected against mortality compared with
patients who did not receive ART (hazard ratio 0.36,
95% CI 0.14–0.91)
Haar et al, 200742 Netherlands Retrospective observational study of national data
1993–2001 spanning pre-ART and ART era
Compared with 1993–1995, adjusted odds of death
during 1999–2001 was 0.46 (95%CI, 0.24–0.89),
whereas no such change was observed among
patients who had TB and were not infected with HIV
Varma et al, 200970 Thailand Prospective multicenter observational study
(n 5 667) comparing patients receiving
and not receiving ART
Adjusted hazards of death among those who received
ART was 0.16 (95%CI, 0.07–0.36)
Velasco et al, 200971 Spain Retrospective observational cohort 1987–2004
(n 5 313) comparing patients receiving and
not receiving ART
Compared with no ART, initiation of ART within the
first 2 months of TB treatment was associatedwith an
adjusted hazards of death of 0..37 (95%CI, 0.17–0.66)
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Lawn et al696IMPACT OFANTIRETROVIRALS ONMORTALITYRISK
TB case fatality rates (the proportion of patients
dying while receiving antituberculosis treatment)
in Africa are 16% to 35% among patients who
are infected with HIV and not receiving ART and
4% to 9% among individuals who were not in-
fected with HIV.41 The authors identified
observational studies (n 5 8) that provided infor-
mation on the impact of ART on survival of patients
who have HIV-associated TB (Table 3). Of these,
half were from high-income countries and half
were from resource-limited settings.
One study using national data from The
Netherlands found a 54% reduction in risk of death
of patients who had HIV-associated TB treated in
the ART era compared with in the pre-ART era.42
Of seven further studies, six found that use of
ART was associated with significant reductions
in mortality risk of 64% to 95% in adjusted
analyses (see Table 3). The remaining study from
Malawi found no such association but analyses
were not adjusted for CD4 cell counts and ART
was not commenced during the intensive phase
of TB treatment when most deaths occurred.43
A key issue that remains to be resolved
regarding the clinical management of patients
who have HIV-associated TB is the optimal time
to start ART during TB treatment. Early mortality
rates are extremely high among patients waiting
to start ART in resource-limited settings.44,45
However, early initiation of ART in those who
have HIV-associated TB increases the risk of TB
immune reconstitution disease.46 This increase is
associated with mortality risk in a small proportion
of patients46,47 but may be greater in those who
have neurologic involvement.48 Overall, the risk/
benefit ratio is likely to favor initiation of ART in
the initial weeks of TB treatment, but the outcome
of randomized controlled trials are awaited.ANTIRETROVIRALS AND TUBERCULOSISTREATMENT OUTCOMES
Data concerning the impact of ART on TB treat-
ment outcomes other than death are scarce. A
large retrospective observational cohort study in
San Francisco reported that use of ART was asso-
ciated with significant shortening of the time to
smear and culture conversion.49 A systematic
review of 32 studies50 and recently published
data from Rio de Janeiro, South African gold
mines, and San Francisco49,51,52 confirm that
patients who have HIV-associated TB are at
increased risk of recurrent disease, especially
those who have low CD4 cell counts. Variousstrategies can be used to address high recurrence
rates, including prolongation of the duration of TB
therapy49,53 and use of secondary isoniazid
prophylaxis.54,55 However, more recent data from
a study in Brazil have now shown that recurrence
rates were halved in patients who had TB who
received ART.51 It remains to be determined
whether combining ART and isoniazid has an
additive effect.SUMMARY
The HIV-associated TB epidemic is undermining
progress toward TB control and additional inter-
ventions must be used in combination with the
DOTS strategy in resource-limited settings.
Observational cohort studies in a wide range of
settings have demonstrated that the use of ART
is associated with a 54% to 92% reduction in TB
incidence rates and a halving of the risk of TB
recurrence. ART is also a potent means of
improving the survival of those who have HIV-
associated TB, reducing mortality rates by 64%
to 95%. Thus, ART confers huge benefits to
individual patients.
However, limited data are available concerning
the effects of ART on TB rates at a population
level. Mathematical modeling and a range of
empiric observations suggest that this may be
limited, largely because of the high burden of TB
that occurs before ART initiation and the persis-
tence of TB rates several-fold higher than back-
ground rates during long-term ART. Thus, ART is
likely to have limited impact on lifetime cumulative
risk of TB. To enhance the impact on community
TB control, it is likely that ART will need to be
implemented with high-population coverage and
at much higher CD4 cell counts than is currently
the case. Adjunctive interventions, such as those
included in the 3I’s policy, may help reduce rates
further.
Despite the likely limited impact on TB rates at
a community level, ART nevertheless transforms
the prognosis of patients who have HIV-associ-
ated TB. By reducing mortality rates, ongoing
ART scale-up may accelerate progress toward
the MDG TB control target of halving the 1990
mortality rate by 2015.REFERENCES
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